Across TCGA pan-cancer cohorts, ZGPAT Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZGPAT data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZGPAT Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZGPAT expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, UCEC, and LUAD are the cancer types where ZGPAT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	1.000	0.322	.021	17	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	III,IV	0.036	0.673	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZGPAT tumor-vs-normal RNA expression · all ZGPAT data types